RLAY Relay Therapeutics, Inc.
Stable Earnings Power
F 25.2 / 100 pillar composite

AlphaQuality composite grade, weighted for stable earnings power businesses.

⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.

Grade overrides the 25.2 pillar composite — hard gates always win.

Profitability

Weight: 20%
D- 30
  • 5yr Avg ROIC -30.9%
  • Operating Margin Trend +3808.61 pp/yr

Capital Efficiency

Weight: 15%
F 0
  • 5yr Avg ROE -41.8%
  • 5yr Share-Count CAGR 13.7%

Growth Quality

Weight: 15%
F 12
  • 5yr Revenue CAGR -28.6%
  • Revenue-Growth Years (5) 2/5

Cash Generation

Weight: 15%
F 0
  • 5yr FCF Margin -5016.4%
  • 5yr FCF/NI Conversion 0.00x

Balance Sheet

Weight: 20%
C 55
  • Net Debt / EBITDA 10.00x
  • Interest Coverage (EBIT/Int) 30.00x
  • Altman Z-Score 40.56

Stability

Weight: 15%
D+ 42
  • Negative-Revenue Years (5) 3/5
  • Piotroski F-Score 4

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Dumping

1 of 1 gurus held; 1 new buy; 2 full exits.

Holders
1
Avg Δ position
New buys
1
Full exits
2
As of Q2 2026